SCHEMBL496636

SCHEMBL496636

N[C@H](Cc1ccccc1)[C@@H](O)CN1CCC[C@H]1c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
SLC6A4 P31645 5/20 0.41
SLC6A3 Q01959 5/20 0.41
SLC6A2 P23975 3/20 0.41
ALDH1A1 P00352 1/20 0.41
ADAM17 P78536 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL496637 1.00 L3MBTL1 (0.49) L3MBTL1SLC6A4SLC6A3SLC6A2ALDH1A1
Hydrochloric Acid SCHEMBL495749 0.99 L3MBTL1 (0.48) L3MBTL1SLC6A4SLC6A3SLC6A2ALDH1A1
SCHEMBL496923 0.92 F2 (0.40) L3MBTL1MEN1KMT2A
SCHEMBL496245 0.92 F2 (0.40) L3MBTL1MEN1KMT2A
SCHEMBL496243 0.92 F2 (0.40) L3MBTL1MEN1KMT2A
Hydrochloric Acid SCHEMBL495938 0.91 F2 (0.41) L3MBTL1MEN1KMT2A
Hydrochloric Acid SCHEMBL495939 0.91 F2 (0.41) L3MBTL1MEN1KMT2A
SCHEMBL6981178 0.78 SLC6A4 (0.38) SLC6A4SLC6A3SLC6A2
SCHEMBL8880117 0.78 F2 (0.39) SLC6A4SLC6A3SLC6A2MEN1KMT2A
SCHEMBL496353 0.77 SPHK2 (0.45) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 EP disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
WO-2007015805-A1 1-AMINO LINKED COMPOUNDS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 L3MBTL1 3185/4885SLC6A4 289/4885SLC6A3 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.